###### Key questions

What is already known about this subject?
=========================================

-   Myocardial fibrosis as detected by late gadolinium enhancement (LE) in cardiac MRI (cMRI) is associated with morphological and functional impairments including increased myocardial hypertrophy and myocardial stiffness.

-   Enzyme replacement therapy is less effective in patients with Fabry disease (FD) already showing myocardial fibrosis.

What does this study add?
=========================

-   Our results suggest that diastolic dysfunction is closely linked to LE in FD; however, cardiac involvement (LE) may also appear in some patients with FD in the absence of detectable systolic and diastolic dysfunction.

How might this impact on clinical practice?
===========================================

-   cMRI should be routinely applied to patients with FD to detect LE as potential first sign of cardiac involvement, implicating an indication for the initiation of specific therapy.

-   The impact of enzyme replacement on LE in patients with FD without detectable systolic and diastolic dysfunction and renal dysfunction remains to be determined.

Introduction {#s1}
============

Fabry disease (FD) is an X-linked multisystem disorder characterised by alpha-galactosidase A enzyme deficiency leading to progressive accumulation of globotriaosylceramide in lysosome carrying cells.[@R1] The occurrence of cardiomyopathy in FD is an ominous prognostic sign and today represents the leading cause of death in these patients.[@R2] This cardiomyopathy is characterised by left ventricular (LV) hypertrophy, prominently hypertrophied papillary muscles, myocardial replacement fibrosis,[@R5] right ventricular dysfunction[@R9] and rhythm disorders.[@R10]

Fibrotic replacement of myocardial fibres is another hallmark of disease progression in FD. Replacement fibrosis can be detected by cardiac MRI (cMRI) through visualisation of late gadolinium enhancement (LE).[@R11] Experimental and clinical studies showed that the extent of LE is associated with increased myocardial stiffness and the degree of diastolic dysfunction in various cardiovascular diseases.[@R12] Global systolic function often remains preserved in FD until its terminal stage; however, the development of more subtle alterations such as diastolic function frequently evades routine diagnostics. In particular, the association of diastolic dysfunction with myocardial replacement fibrosis in FD is not fully understood. Echocardiography plays a central role in the assessment of LV diastolic function. The diastolic strain rate measured by two-dimensional speckle-tracking imaging (STI) emerged as a feasible surrogate of LV filling pressure. For example, the ratio of early diastolic mitral inflow velocity to global early diastolic strain rate was particularly sensitive in detecting diastolic dysfunction in patients with acute myocardial infarction, superior to conventional diastolic indices.[@R16]

Although clinical studies demonstrated that specific enzyme replacement therapy (ERT) successfully alleviated the symptom burden in FD, established Fabry cardiomyopathy was generally poorly responsive.[@R2] Since treatment success critically depends on early therapy initiation, detection of subtle cardiac involvement might aid screening of patients with FD likely to benefit from early ERT.

We therefore investigated in patients with FD and preserved left ventricular ejection fraction (LVEF) the association between systolic/diastolic dysfunction as determined by echocardiography and myocardial fibrosis as detected by cMRI. We hypothesised that in these patients: (1) LE is linked not only to reduced longitudinal systolic strain (LS_sys) but also to diastolic dysfunction; (2) diastolic or systolic dysfunction is a prerequisite of replacement fibrosis indicated by LE; (3) STI-derived diastolic parameters might be superior to conventional diastolic indices for the staging of cardiac involvement.

Methods {#s2}
=======

Study population {#s2a}
----------------

The database of the Würzburg Fabry Center for Interdisciplinary Treatment was searched for genetically proven patients with FD referred to the Center between 2006 and 2015. The structure of the center and the methodology of clinical phenotyping of patients with FD have been reported in detail elsewhere.[@R19] All patients underwent both transthoracic echocardiography and cMRI within a 1 week interval. Out of 214 consecutive patients with FD, 165 had viable cMRI scans; 19 patients were excluded due to compromised LVEF (n=9) or reasons promoting LE (n=1 diabetes; n=9 coronary artery disease), rendering 146 patients with echocardiographically measured LVEF ≥50% suitable for the current analysis (online [supplementary eFigure 1](#SP1){ref-type="supplementary-material"}). The study was conducted in accordance to the Declaration of Helsinki. Written informed consent was obtained from all patients or their guardians. cMRI was performed using a 1.5 Tesla full-body MRI scanner (Magnetom Symphony Quantum/Avanto; Siemens Medical Systems, Erlangen, Germany). LE images were acquired 15 min after intravenous injection of 0.2 mmol/kg gadopentetate dimeglumine, using T1-weighted inversion recovery imaging sequences (field of view 240×320 mm^2^, matrix size 165×256, slice thickness 8 mm, echo time 3.4 ms, repetition time 7.5 ms). LE was rated by two radiologists as described before[@R19] who were kept blinded to all clinical data. Areas with signal intensity above the average of the normal myocardium plus 2 SDs were defined as LE positive.
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Conventional echocardiography measurements {#s2b}
------------------------------------------

A standard echocardiographic examination was performed on a Vivid 7 or 9e echo machine (GE Vingmed, Horten, Norway). Measurements were performed offline by a single investigator (DL) according to recommended guidelines as previously described.[@R20] Pulsed-wave Doppler and tissue Doppler were recorded and diastolic parameters including mitral inflow peak early (E-wave) and late (A-wave) velocities, E/A ratio, deceleration time (DT) of E velocity and isovolumetric relaxation time (IVRT) were measured.[@R21] Diastolic filling patterns (ie, normal, impaired relaxation, pseudonormal and restrictive filling) were defined according to current guidelines.[@R21] In brief, a normal filling pattern was defined as mitral inflow E/A ratio=0.8 to 2, DT=140 to 240 ms, IVRT=70 to 100 ms; impaired relaxation defined as the E/A ratio ≤0.8, DT ≥240 ms, IVRT\>100 ms; pseudonormal filling defined as the E/A ratio=0.8 to 1.5, DT and IVRT\<90 ms; restrictive pattern defined as the E/A ratio ≥2, DT \<140 ms and IVRT≤70 ms. If necessary, a Valsalva manoeuvre was performed to distinguish between normal and pseudonormal filling.[@R21] Tissue-Doppler derived mitral annular peak early velocity (e′) at the septal and lateral mitral annulus was acquired, and septal, lateral and averaged E/e′ ratios were calculated, respectively. Diastolic dysfunction was further graded by an integral approach based on the assessment of diastolic filling pattern, E/e′, and left atrial volume together with tricuspid regurgitation velocity.[@R21]

Speckle-tracking imaging {#s2c}
------------------------

STI analysis was performed using EchoPAC software (GE, Horten, Norway) as described previously.[@R20] Longitudinal peak systolic strain rate (LSr_sys) and LS_sys, longitudinal early (LSr_E) and late (LSr_A) diastolic peak strain rates of each segment were measured. Global deformation values were acquired by averaging strain rate and strain values of all 16 segments. The ratio of E to global LSr_E (E/LSr_E) was calculated. Images and loops were analysed by an experienced echocardiographer (DL) with \>6 years of experience in STI analysis, who was blinded to all patient information, including the final histopathological diagnosis.

Renal function {#s2d}
--------------

Glomerular filtration rate (GFR) was measured using technetium 99m-diethylene triamine penta-acetic acid aerosol clearance (Tc99m-DTPA) and estimated according to the Modification of Diet in Renal Disease formula.

Data analysis {#s2e}
-------------

Continuous variables were expressed as mean±SD or median (quartiles). Categorical variables were presented as count (per cent). Differences on continuous data with normal distribution across groups were compared using unpaired Student 's t-test. Variables with skewed distribution were tested by Mann-Whitney U-test. Categorical data were compared using a similar approach employing χ^2^ and Fisher's exact test, as appropriate. Multivariable logistic regression was conducted to define the independent determinants for LE after adjustment for age, sex, body mass index, NYHA functional class and GFR. Receiver operating characteristic (ROC) analysis was performed to identify the diagnostic performance of markers for LE. For the determination of the cut-off values of septal E/e′, we used the cut-off value with maximum sensitivity (\<7) to rule out the presence of LE, and the cut-off value with maximum specificity (\>14.8) to predict the presence of LE. The respective cut-off values were determined by maximising sensitivity and specificity. Statistical significance was defined as p\<0.05 (two-tailed test). Statistical analysis was performed using IBM SPSS, version 23 for Windows (IBM, New York, USA).

Results {#s3}
=======

Baseline clinical characteristics {#s3a}
---------------------------------

Clinical characteristics of patients with FD are summarised in [table 1](#T1){ref-type="table"}. LE was detected by cMRI in 57 out of 146 (39%) patients with FD with preserved LVEF. Patients were divided into two groups with and without LE. The mean age was 39±14 years, and 57 (39%) patients were men. Patients with LE were older than those without LE (48±11 vs 33±12 years, p\<0.001). The percentage of patients with NYHA functional class III--IV was significantly higher in the LE group than in the no LE group (14.1% vs 2.2%, p\<0.001). Prevalence of kidney dysfunction and levels of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) were significantly higher in the LE group than in the no LE group (both p\<0.05).

###### 

Baseline clinical characteristics

                                        Total               No LE               LE                  P values
  ------------------------------------- ------------------- ------------------- ------------------- ----------
  Age at baseline (years)               39±14               33±12               48±11               \<0.001
  Male (n (%))                          57 (39.0)           34 (38.2)           23 (40.4)           0.795
  BMI (kg/m²)                           24±5                23±4                25±5                0.006
  BSA (m²)                              1.8±0.2             1.8±0.2             1.8±0.2             0.033
  Heart rate (beats/min)                67±12               68±12               66±12               0.228
  Systolic blood pressure (mm Hg)       123±19              120±19              127±19              0.040
  Diastolic blood pressure (mm Hg)      80±12               79±11               83±12               0.035
  NYHA class (n (%))                                                                                \<0.001
   I                                    112 (76.7)          79 (88.8)           33 (57.9)           
   II                                   24 (16.4)           8 (9.0)             16 (28.1)           
   III                                  9 (6.2)             2 (2.2)             7 (12.3)            
   IV                                   1 (0.7)             0                   1 (1.8)             
  Lyso-Gb3 (ng/mL)                      9.5 (4.1--24.1)     8.9 (2.8--63.0)     10.6 (6.9--19.0)    0.782
  Reduced enzyme activity (n (%))       123 (84.2)          76 (85.4)           47 (82.5)           0.635
  Enzyme replacement therapy            79 (54.1)           42 (53.2)           37 (46.8)           0.036
  Kidney function                                                                                   
   GFR (DTPA) (mL/min)                  105±32              112±28              93±35               0.001
   Creatinine (mg/dL)                   0.8 (0.7--0.9)      0.8 (0.7--0.9)      0.9 (0.7--1.0)      0.002
   Cystatin C (mg/L)                    0.78 (0.70--0.90)   0.76 (0.64--0.84)   0.83 (0.73--1.08)   0.001
   Proteinuria (n (%))                  50 (35.0)           23 (25.8)           27 (50.0)           0.003
   CKD stage III--V (n (%))             17 (11.6)           9 (10.1)            8 (14.0)            0.471
   Dialysis (n (%))                     7 (4.8)             2 (2.2)             5 (8.8)             0.110
   Kidney transplantation (n (%))       3 (2.1)             0                   3 (5.3)             0.058
  NT-proBNP (pg/mL)                     91 (41--261)        69 (30--132)        267 (81--773)       \<0.001
  Cardiovascular history (n (%))                                                                    
   Hypertensive heart disease           40 (27.4)           18 (20.2)           22 (38.6)           0.015
   ICD/PM                               1 (0.7)             0                   1 (1.8)             0.390
  Neurological manifestations (n (%))                                                               
   Depression                           13 (8.9)            4 (4.5)             9 (15.8)            0.034
   TIA/stroke                           27 (18.5)           15 (16.9)           12 (21.1)           0.524
   Tinnitus                             53 (36.3)           28 (31.5)           25 (43.9)           0.129
   Hearing loss                         28 (19.2)           15 (16.9)           13 (22.8)           0.373
   Dysarthria                           4 (2.7)             0                   4 (7.0)             0.011
   Heat intolerance                     72 (49.3)           40 (44.9)           32 (56.1)           0.235

Continuous variables are presented as mean±SD or median (quartiles), and categorical variables are presented with counts and percentages. P\<0.05 vs no LE group.

BMI, body mass index; BSA, body surface area; CKD, chronic kidney disease; GFR (DTPA): glomerular filtration rate from 99mTc-diethylene triamine penta-acetic acid renography; ICD, implantable cardioverter defibrillator; LE, late gadolinium enhancement; Lyso-Gb3: plasma globotriaosylsphingosine; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PM, pacemaker; TIA, transient ischaemic attack.

Cardiac MRI {#s3b}
-----------

Mean LVEF as measured by cMRI was 64%±8%, and similar between groups ([table 2](#T2){ref-type="table"}). LV mass index was higher in the LE group than in the no LE group (95±32 vs 71±19 g/m², p\<0.001). As shown in online [supplementary eFigure 2A](#SP2){ref-type="supplementary-material"}, LE was predominantly detected at basal and mid segments of the inferolateral wall (82.8% in segment 5 and 51.6% in segment 11).
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###### 

Cardiac MRI characteristics

                  Total     No LE     LE        P values
  --------------- --------- --------- --------- ----------
  LVEF (%)        64±8      62±7      66±7      0.004
  LVMI (g/m²)     80±28     71±19     95±32     \<0.001
  EDVI (mL/m²)    76±18     77±15     74±21     0.281
  ESVI (mL/m²)    28±10     29±9      25±11     0.037
  SVI (mL/m²)     48±12     48±10     47±15     0.779
  CI (L/min/m²)   3.2±0.8   3.3±0.8   3.1±0.9   0.073

Continuous variables are presented as mean±SD.

P\<0.05 vs no LE group.

CI, cardiac index; EDVI, end-diastolic volume indexed to body surface area; ESVI, end-systolic volume indexed to body surface area; LE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass indexed to body surface area; SVI, stroke volume indexed to body surface area.

Echocardiography {#s3c}
----------------

The mean LVEF derived from echocardiography was 66%±6% and similar between groups ([table 3](#T3){ref-type="table"}). The tricuspid annular plane systolic excursion, a parameter reflecting right ventricular function,[@R22] was within the normal range (mean 23.0±3.9 mm) in the total sample. LV wall thickness, left atrium volume index (LAVI), septal and lateral E/e′ were significantly higher, while septal and lateral e′ were significantly lower in the LE group than in the no LE group. The proportion of moderate to severe diastolic dysfunction[@R23] was significantly higher in the LE group than the no LE group (42.1% vs 2.1%, p\<0.001).

###### 

Echocardiographic characteristics

                                                    Total        No LE        LE           P values
  ------------------------------------------------- ------------ ------------ ------------ ----------
  Standard echocardiography                                                                
   Cardiac dimensions                                                                      
    LVEDD (mm)                                      47±5         47±5         46±6         0.150
    LVESD (mm)                                      29±4         30±4         28±5         0.012
    IVSd (mm)                                       10.0±2.4     9.0±1.5      11.7±2.6     \<0.001
    LVPWd (mm)                                      9.9±2.4      8.9±1.7      11.5±2.5     \<0.001
    LVMI (g/m²)                                     92±30        82±23        108±32       \<0.001
    RWT                                             0.43±0.13    0.38±0.08    0.51±0.15    \<0.001
    RVD_middle (mm)                                 27±4         27±5         26±5         0.478
    RAA (cm²)                                       14±3         14±3         14±3         0.458
    LAVI (mL/m²)                                    24±9         21±6         28±11        \<0.001
   RV function                                                                             
    TAPSE (mm)                                      23.0±3.9     23.8±3.7     21.8±4.0     0.002
    sPAP (mm Hg)                                    26±7         25±5         27±9         0.136
   LV systolic function                                                                    
    LVEF (%)                                        66±6         65±6         68±6         0.007
   LV diastolic function                                                                   
    E wave (cm/s)                                   87±19        86±16        89±21        0.343
    E/A ratio                                       1.47±0.54    1.5±0.5      1.4±0.6      0.653
    DT (ms)                                         207±50       203±43       214±58       0.173
    IVRT (ms)                                       89±24        79±17        104±27       \<0.001
    Septal e′ (cm/s)                                8.6±3.3      10.1±2.9     6.3±2.3      \<0.001
    Septal E/e′ ratio                               11.7±5.8     9.1±3.1      15.8±6.7     \<0.001
    Lateral e′ (cm/s)                               11.9±4.2     13.7±3.8     9.2±3.1      \<0.001
    Lateral E/e′ ratio                              8.3±3.7      6.7±2.0      10.7±4.3     \<0.001
    Diastolic dysfunction                                                                  \<0.001
     Normal                                         95 (65.1)    76 (85.4)    19 (33.3)    
     Mild                                           24 (16.4)    10 (11.2)    14 (24.6)    
     Moderate                                       19 (13.0)    3 (2.1)      16 (28.1)    
     Severe                                         8 (5.5)      0            8 (14.0)     
  Speckle-tracking imaging (18 segments averaged)                                          
   LS_sys (%)                                       −17.9±3.3    −18.9±2.5    −16.3±3.7    \<0.001
   LSr_sys (s^−1^)                                  −0.99±0.16   −1.03±0.15   −0.94±0.17   0.001
   LSr_E (s^−1^)                                    1.36±0.41    1.49±0.39    1.16±0.36    \<0.001
   LSr_A (s^−1^)                                    0.66±0.23    0.66±0.22    0.65±0.25    0.938
   E/LSr_E (cm)                                     69.0±25.3    60.5±16.3    82.6±30.8    \<0.001

Continuous variables are presented as mean±SD, and categorical variables are presented with counts and percentages.

P\<0.05 vs no LE group.

DT, deceleration time of E wave; E wave, mitral inflow early diastolic filling velocity; E/A ratio, the ratio of mitral inflow early filling velocity to late diastolic filling velocity; E/e′, the ratio of early diastolic mitral inflow velocity to mitral annular tissue velocity; E/LSr_E, the ratio of mitral inflow early diastolic filling velocity to LSr_E; e′, tissue Doppler-derived mitral annular early diastolic velocity; IVRT, isovolumetric relaxation time; IVSd, end-diastolic interventricular septal thickness; LAVI, left atrial volume indexed to body surface area; LE, late gadolinium enhancement; LS_sys, longitudinal systolic strain; LSr_A, longitudinal late diastolic strain rate; LSr_E, longitudinal early diastolic strain rate; LSr_sys, longitudinal systolic strain rate; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; LVMI, left ventricular mass indexed to body surface area; LVPWd, end-diastolic posterior wall thickness; RAA, end-systolic right atrial area; RV, right ventricle; RVD, end-diastolic mid-right ventricular diameter; RWT, relative wall thickness sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion.

Longitudinal systolic and diastolic strain and strain rate {#s3d}
----------------------------------------------------------

Global LS_sys, LSr_sys and LSr_E were significantly reduced, and E/LSr_E ratio was significantly increased in the LE group compared with the no LE group, while global LSr_A was similar between groups ([table 3](#T3){ref-type="table"}). Segmental LS_sys and LSr_E were significantly lower in the LE group than in the no LE group, especially at the mid-lateral segment. In line with the distribution of LE (online [supplementary eFigure 2](#SP1){ref-type="supplementary-material"}), LS_sys and LSr_E were predominantly lower in the basal and mid-lateral wall (segments 5--6 and 11--12).

Echocardiographic parameters associated with LE {#s3e}
-----------------------------------------------

Associations between clinical and echocardiographic parameters and LE are listed in [table 4](#T4){ref-type="table"}. NT-proBNP levels, end-diastolic interventricular septal thickness, left ventricular mass indexed to body surface area, LAVI, septal and lateral E/e′ ratio, diastolic dysfunction grading, global LS_sys, E/LSr_E, LS_sys and LSr_E at mid-lateral segments were all associated with LE in patients with FD with preserved LVEF after adjustment for age, sex, body mass index, New York Heart Association functional class and Tc99m-DTPA clearance. The ROC analysis showed that septal E/e′ was the best echocardiographic marker indicating the presence of LE in patients with FD with preserved LVEF (area under the curve (AUC) 0.86; [figure 1](#F1){ref-type="fig"}). LE was not detected in patients with septal E/e′\<7 (sensitivity 100% and specificity 23.6%), while septal E/e′\>14.8 was strongly associated with the presence of LE with a specificity of 97.8% and a sensitivity of 49.1% ([table 5](#T5){ref-type="table"}). LE was also detected in 29 out of 116 patients with septal E/e′≤14.8, indicating there is only a limited negative predictive value to exclude LE using a threshold of E/e′≤14.8.

![Receiver operating characteristic analyses of NT-proBNP and echocardiographic determinants for late gadolinium enhancement (LE) in patients with Fabry disease with preserved left ventricular ejection fraction. AUC, area under curve; E/e′, the ratio of early diastolic mitral inflow velocity to mitral annular tissue velocity; IVSd, end-diastolic interventricular septal thickness; NT-proBNP, N-terminal pro-brain natriuretic peptide; LS_sys, longitudinal systolic strain; LSr_E, longitudinal early diastolic strain rate; E/LSr_E, the ratio of mitral inflow early diastolic filling velocity to LSr_E; LSr_ivr, longitudinal peak strain rate during isovolumetric relaxation time.](openhrt-2018-000803f01){#F1}

###### 

Independent determinants for LE in patients with Fabry disease with preserved LVEF

                                   Spearman's r   P values   OR[\*](#tblfn9){ref-type="fn"}   95% CI          P values   AUC    95% CI         P values
  -------------------------------- -------------- ---------- -------------------------------- --------------- ---------- ------ -------------- ----------
  Clinical marker                                                                                                                              
   NT-proBNP (pg/mL)†              0.47           \<0.001    1.85                             1.18 to 2.92    0.008      0.78   0.70 to 0.85   \<0.001
  Echocardiographic markers                                                                                                                    
   IVSd (mm)                       0.55           \<0.001    1.65                             1.25 to 2.18    \<0.001    0.82   0.75 to 0.89   \<0.001
   LVMI (g/m²)                     0.42           \<0.001    1.03                             1.01 to 1.05    0.002      0.75   0.66 to 0.83   \<0.001
   EF (%)                          0.23           0.006      1.05                             0.97 to 1.13    0.222      0.63   0.54 to 0.73   0.006
   LAVI (mL)                       0.39           \<0.001    1.10                             1.03 to 1.18    0.004      0.73   0.64 to 0.82   \<0.001
   Septal E/e′                     0.60           \<0.001    1.30                             1.13 to 1.49    \<0.001    0.86   0.79 to 0.92   \<0.001
   Lateral E/e′                    0.54           \<0.001    1.34                             1.11 to 1.62    0.002      0.82   0.75 to 0.89   \<0.001
   Diastolic dysfunction grading   0.56           \<0.001    2.98                             1.61 to 5.526   0.001      0.78   0.70 to 0.86   \<0.001
  STI markers                                                                                                                                  
   Global LS_sys (%)               0.38           \<0.001    1.16                             1.00 to 1.34    0.047      0.73   0.65 to 0.81   \<0.001
   E/LSr_E (cm)                    0.42           \<0.001    1.03                             1.00 to 1.05    0.015      0.74   0.65 to 0.82   \<0.001
   Mid-lateral LS_sys (%)          0.51           \<0.001    1.20                             1.07 to 1.34    0.002      0.83   0.75 to 0.90   \<0.001
   Mid-lateral LSr_E (s^−1^)       −0.44          \<0.001    0.38                             0.15 to 0.95    0.034      0.76   0.68 to 0.84   \<0.001

\*Adjusted for age, sex, BMI, NYHA functional class, GFR (DTPA).

†Ln transformed.

AUC, area under the curve; BMI, body mass index; E/e′, the ratio of early diastolic mitral inflow velocity to mitral annular tissue velocity; EF, ejection fraction; GFR (DTPA), glomerular filtration rate from 99mTc-diethylene triamine penta-acetic acid; IVSd, end-diastolic interventricular septal thickness; LAVI, left atrial volume indexed to body surface area; LE, late gadolinium enhancement; LS_sys, longitudinal systolic strain; LSr_E, longitudinal early diastolic strain rate; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass indexed to body surface area; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; STI, speckle-tracking imaging.

###### 

Diagnostic performance of septal E/e′ for LE in patients with Fabry disease

  --------------------------------------------------------------------------------------------------------------------------------------
                             No LE\   LE\      Sensitivity (95% CI)   Specificity (95% CI)   PPV (95% CI)          NPV (95% CI)
                             (n=89)   (n=57)                                                                       
  -------------------------- -------- -------- ---------------------- ---------------------- --------------------- ---------------------
  Septal E/e′\<7 (n=21)      21       0        100 (92.1 to 100)      23.6 (15.5 to 34.0)    45.6 (36.7 to 54.7)   100 (80.7 to 100)

  Septal E/e′≥7 (n=125)      68       57                                                                           

  Septal E/e′\<10 (n=73)     62       11       80.7 (67.7 to 89.5)    69.7 (58.9 to 78.7)    63.0 (50.9 to 73.8)   84.9 (74.2 to 91.9)

  Septal E/e′≥10 (n=73)      27       46                                                                           

  Septal E/e′\<14 (n=109)    84       25       56.1 (42.4 to 69.0)    94.4 (86.8 to 97.9)    86.5 (70.4 to 94.9)   77.1 (67.8 to 84.3)

  Septal E/e′≥14 (n=37)      5        32                                                                           

  Septal E/e′≤14.8 (n=116)   87       29       49.1 (35.8 to 62.6)    97.8 (91.3 to 99.6)    93.3 (76.5 to 98.8)   75.0 (65.9 to 82.4)

  Septal E/e′\>14.8 (n=30)   2        28                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------

E/e′, the ratio of early diastolic mitral inflow velocity to mitral annular tissue velocity; LE, late gadolinium enhancement; PPV, positive predictive value; NPV, negative predictive value.

Based on above findings, we established a framework for screening LE of patients with FD using echocardiography in the clinical setting. [Figure 2](#F2){ref-type="fig"} shows an algorithm employing echocardiographic parameters suggestive of LE in patients with FD with preserved LVEF.

![Screening algorithm by the use of echocardiographic parameters suggestive of late gadolinium enhancement (LE) in patients with Fabry disease with preserved left ventricular ejection fraction. 95% CI for proportions was calculated according to the efficient-score method (corrected for continuity) described by R. Newcombe, based on the procedure outlined by E. B. Wilson in 1927. E/e ′, the ratio of early diastolic mitral inflow velocity to mitral annular tissue velocity; IVSd, end-diastolic interventricular septal thickness; LSr_E, longitudinal early diastolic strain rate.](openhrt-2018-000803f02){#F2}

In addition, we defined 45 patients with FD with neither kidney nor cardiac involvement, that is, normal renal function (Tc99m-DTPA clearance \>90 mL/min/1.73 m²), normal NT-proBNP (\<100 pg/mL), normal systolic function (global longitudinal strain \>18%), normal LV wall thickness (IVSd \<11 mm) and normal LA (LAVI\<34 mL/m²). Local LE at basal inferior and lateral wall was still evidenced in four (8.9%) patients, indicating LE can be present even in the absence of measurable cardiac/renal dysfunction in patients with FD. On the other hand, LE was not detected in 41.9% of (18/43) patients with a Tc99m-DTPA clearance of 60--90 mL/min/1.73 m² (mild renal dysfunction) and in 41.2% (7/17) of patients with a Tc99m-DTPA clearance of \<60 mL/min/1.73 m² (moderate to severe renal dysfunction), reflecting vast pathological variance of FD.[@R4]

D**iscussion** {#s4}
==============

Our understanding of the pathogenesis of the Fabry cardiomyopathy significantly improved over the last two decades, but important features of Fabry cardiomyopathy, such as the inter-relationship between diastolic dysfunction, systolic dysfunction, hypertrophy and myocardial fibrosis remain elusive. To the best of our knowledge, this is the first report focusing on the association of both classical and modern diastolic/systolic indices with the presence of myocardial replacement fibrosis in patients with FD with preserved LVEF. The major findings of the present study in patients with FD with preserved LVEF are (1) LE is significantly associated with age, kidney function, NT-proBNP, LV hypertrophy, and systolic and diastolic dysfunction; (2) septal E/e′ ratio appears to be the best echocardiographic marker associated with LE; (3) septal E/e′\>14.8 is strongly associated with the presence of LE and (4) LE can sometimes be detected in FD in the absence of additional measurable cardiac/renal dysfunction.

LE in patients with FD with preserved LVEF {#s4a}
------------------------------------------

The appearance of myocardial replacement fibrosis is an acknowledged key feature in the cardiac pathophysiology of FD.[@R5] It has been postulated that tissue ischaemia secondary to endothelial accumulation of glycosphingolipids in the microvasculature might accelerate the development of myocardial fibrosis in FD, with the inferolateral wall representing the predominantly affected segment.[@R5] Previous cMRI studies from our group found that LE was present in 33% of female and 48% of male patients with FD.[@R26] In line with previous findings from others as well as our own group,[@R19] we here confirmed that LE mostly presented at basal and mid-segments of the inferolateral wall, and mid-lateral LS_sys was often significantly reduced despite preserved global LS_sys ([figure 1](#F1){ref-type="fig"}). However, a recent biopsy study revealed that interstitial myocardial fibrosis was already detectable at very early stages of the Fabry cardiomyopathy.[@R27] Accordingly, the current study confirmed that LE can be detected at least in some patients with FD in the absence of measurable cardiac and renal dysfunction, suggesting that LE may appear at very early stages of the disease and is neither necessarily related to prior larger-scale morphological nor functional impairments. Pathophysiological explanation might be provided in a current study using cMRI T2 mapping, showing that (chronic) inflammation might contribute to the development of LE in FD.[@R28] In line with these findings, we could just recently show that LE is not necessarily progressive, but might even regress slightly under appropriate therapy.[@R29] These observations might not be specific or limited to FD, since similar phenomena were evidenced recently also in patients with aortic stenosis undergoing aortic valve replacement.[@R30]

Association of systolic and diastolic dysfunction with LE {#s4b}
---------------------------------------------------------

Progressive LV hypertrophy, diastolic dysfunction and preserved systolic function have been described as the major echocardiographic features of Fabry cardiomyopathy. Pieroni *et al* demonstrated that diastolic dysfunction can already exist prior to the development of LV hypertrophy or systolic dysfunction in patients with Fabry cardiomyopathy, suggesting that diastolic dysfunction might be an early sign of cardiac involvement in patients with FD.[@R31] In line with these findings, we found that diastolic dysfunction was already present in 19% (17/88) of patients with FD with normal LS_sys (\>18%) and normal LVEF in the current patient cohort.

Previous studies also indicated that the tissue Doppler derived diastolic index (ie, e′) could provide satisfactory preclinical evidence for diastolic dysfunction in patients with Fabry cardiomyopathy.[@R31] Shanks *et al* further showed that STI-derived longitudinal systolic strain and diastolic isovolumetric strain rate were superior to other classic echocardiographic parameters for the risk stratification and disease staging in patients with FD.[@R32] Our results indicate that despite a preserved systolic function (LVEF: mean value 66%, range 52% to 80%), a significant proportion of patients with FD (35%) presented with at least mild diastolic dysfunction, as shown by abnormal conventional and STI-derived diastolic deformation indices (LSr_E and E/LSr_E). Moreover, increased LV wall thickness, left atrium volume, septal E/e′, E/LSr_E and reduced septal and lateral e′ were evidenced in the LE group compared with the no LE group, reflecting that diastolic dysfunction is closely linked to LE. Our results further revealed that serum and echocardiographic biomarkers reflecting diastolic function (including the myocardial stress biomarker NT-proBNP, LV wall thickness, LA volume, e′ and E/e′) remained predictive of LE, supporting the close relationship between diastolic dysfunction and replacement myocardial fibrosis in FD. However, the STI-derived diastolic index was not superior to the conventional echocardiographic diastolic index. Indeed, our results showed that e′ and E/e′ were the best echocardiographic markers suggestive of LE in FD, superior to E wave, E/A, and DT, and STI-derived global LSr_E and E/LSr_E.

A recent study demonstrated that E/e′ was associated with myocardial fibrosis detected by cMRI in children with hypertrophic cardiomyopathy.[@R33] In line with these findings, our data showed a close correlation between E/e′ and LE in patients with FD and preserved LVEF. Septal E/e′\<7 indicated absence of LE in patients with FD. On the other hand, LE was detected in 93% of patients with septal E/e′\>14.8. In patients presenting with mid-ranged septal E/e′ (7--14.8), an increased lateral E/e′ (\>13) might provide additional information suggestive of LE.

Limitations {#s4c}
-----------

The patient sample was relatively small in this retrospective study, which could have introduced overoptimism regarding the proposed cut-off values of index test. Future prospective studies are warranted to verify the clinical value of the proposed algorithm, in particular as segmental STI has technical limitations specifically regarding interobserver and intraobserver variability. In our algorithm, we used reduced segmental longitudinal strain/strain rate at mid-lateral wall (ie, LS_midLat and LSrE_midLat) as one screening criteria suggestive of LE, since related changes in this segment belong to pathological feature of cardiac involvement of FD. Of note, however, previous studies showed that single segmental strain values are associated with higher variability in contrast to global longitudinal strain.[@R34] Additionally, potential misclassification in some groups of patients with 'grey zone' E/e′ could be as high as 20% according to our proposed algorithm. This scenario further implies the importance of cMRI examination in patients with FD with preserved LVEF.

Even though the presence of myocardial fibrosis can influence the management of patients with FD, therapeutic approaches might be affected not only by the presence, but more importantly the absolute amount of LE. In the current study, we only investigated the presence or absence of LE and the severity of LE was not analysed. This study limitation particularly needs to be clarified in future studies aiming to observe the clinical outcome of patients with FD with various degrees of LE severity and therapy regimens.

Clinical implications {#s4d}
---------------------

Both echocardiography and MRI examinations are valuable tools for monitoring the cardiac involvement in patients with FD. Even though a close correlation of LE with diastolic functional parameters was found, the current results also show that LE can be detected even in the absence of measurable cardiac involvement at least in some patients with FD. It has been reported that ERT can reduce glycosphingolipid accumulation in the kidney of patients with FD and even clean intracellular deposits.[@R35] ERT also improves outcome, however, is presumably less effective in patients with FD who already developed myocardial fibrosis.[@R17] As a result, our study results strongly support additional routine examinations both by echocardiography as well as by cMRI in patients with FD at risk of organ involvement in order to facilitate a therapy start as early as possible to avoid permanent organ damage. In patients not feasible to undergo MRI, diastolic function as acquired by echocardiography might additionally be used as a surrogate measure to predict presence and evolution of replacement fibrosis.

Conclusions {#s5}
===========

LE is significantly associated with age, kidney function, NT-proBNP, LV hypertrophy, and systolic and diastolic dysfunction in patients with FD with preserved LVEF. In these patients, septal E/e′ ratio is the best echocardiographic marker associated with prevalence of LE. However, diastolic dysfunction is not a prerequisite for LE in FD, since LE can precede measurable functional impairments as very early marker of cardiac involvement.
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